Cat. No.: HY-N1497

Plumbagin

(Synonyms: 2-Methyljuglone)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica, exhibits anticancer and antiproliferative activities.

For research use only. We do not sell to patients.

Purity: 99.74%
CAS No.: 481-42-5
Formula: C₁₁H₈O₃
Molecular Weight:188.18

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Plumbagin Chemical Structure

CAS No.: 481-42-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica, exhibits anticancer and antiproliferative activities^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.4 μM Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
A549	IC₅₀	3 μM Compound: 2	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
A549	IC₅₀	7.2 μM Compound: 2	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
A549	IC₅₀	8.9 μM Compound: PL ; 1	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
ACHN	EC₅₀	3.7 μM Compound: 6	Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay	[PMID: 22313254]
ACHN	EC₅₀	7.3 μM Compound: 6	Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL	[PMID: 22313254]
B16-F10	IC₅₀	1 μM Compound: 2	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
BT-474	IC₅₀	0.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay	[PMID: 22512718]
BT-474	IC₅₀	1.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay	[PMID: 22512718]
DU-145	IC₅₀	5.23 μM Compound: Plumbagin	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HCT-116	IC₅₀	20 μM Compound: 1	Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
HCT-116	IC₅₀	20 μM Compound: 1	Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
HCT-116	IC₅₀	9.8 μM Compound: PL ; 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HEK293	EC₅₀	0.46 μM Compound: 7	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HeLa	IC₅₀	>50 μM Compound: 18a	Inhibition of PCAF in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis Inhibition of PCAF in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis	[PMID: 31195169]
HeLa	IC₅₀	10.2 μM Compound: Plumbagin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 33766765]
HeLa	IC₅₀	20 μM Compound: 18a	Inhibition of P300 in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis Inhibition of P300 in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis	[PMID: 31195169]
HeLa	IC₅₀	25.5 μM Compound: 1a	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24913712]
HeLa	IC₅₀	59 μM Compound: 1b	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	59 μM Compound: 47	Antitumor activity against human HeLa cells assessed as cell growth inhibition Antitumor activity against human HeLa cells assessed as cell growth inhibition	[PMID: 36858050]
HepG2	IC₅₀	10.66 μM Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
HepG2	IC₅₀	9.17 μM Compound: PL ; 1	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HK-2	IC₅₀	23.58 μM Compound: PL ; 1	Cytotoxicity against human HK2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HL-60	IC₅₀	1.1 μM Compound: 2	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HL-60	IC₅₀	1.5 μM Compound: Plumbagin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 to 72 hrs by MTT assay	[PMID: 38458106]
HL-60	IC₅₀	3.67 μM Compound: Plumbagin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 30007564]
HL-60	IC₅₀	8.25 μM Compound: Plumbagin	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 30007564]
Hs 683	IC₅₀	4 μM Compound: 2	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
HT-29	IC₅₀	26.2 μM Compound: 1b	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	26.2 μM Compound: 47	Antitumor activity against human HT-29 cells assessed as cell growth inhibition Antitumor activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 36858050]
HT-29	IC₅₀	4.19 μM Compound: Plumbagin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HUVEC	ED₅₀	0.4 μg/mL Compound: 1	Cytotoxicity against human HUVEC Cytotoxicity against human HUVEC	[PMID: 15270571]
Jurkat	IC₅₀	0.95 μM Compound: 2	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
KB	ED₅₀	0.3 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15270571]
KB	IC₅₀	9.83 μM Compound: Plumbagin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 33766765]
LNCaP	ED₅₀	0.4 μg/mL Compound: 1	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15270571]
LS174T	IC₅₀	9.9 μM Compound: 2	Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
Lu1	ED₅₀	0.3 μg/mL Compound: 1	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15270571]
MCF7	IC₅₀	1 μM Compound: Plumbagin	Cytotoxicity against human MCF7 cells incubated for 7 days by MTT assay Cytotoxicity against human MCF7 cells incubated for 7 days by MTT assay	[PMID: 38458106]
MCF7	IC₅₀	1.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA	[PMID: 38458106]
MCF7	IC₅₀	12.2 μM Compound: 1b	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	12.2 μM Compound: 47	Antitumor activity against human MCF7 cells assessed as cell growth inhibition Antitumor activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36858050]
MCF7	IC₅₀	2.84 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	3 μM Compound: 2	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
MCF7	IC₅₀	3.35 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30810041]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 33234343]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	4.1 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	5.1 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	5.5 μM Compound: 1	Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 22483392]
MCF7/PTX	IC₅₀	3.5 μM Compound: Plumbagin	Cytotoxicity against paclitaxel-resistant human MCF7/PTX cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human MCF7/PTX cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30810041]
MDA-MB-231	IC₅₀	1.5 μM Compound: Plumbagin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA	[PMID: 38458106]
MDA-MB-231	IC₅₀	14.23 μM Compound: 1; PL	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
MDA-MB-231	IC₅₀	21.24 μM Compound: Plumbagin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
MDA-MB-231	IC₅₀	3.5 μM Compound: 1	Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22483392]
MDA-MB-231	IC₅₀	4.4 μM Compound: Plumbagin	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33234343]
MDA-MB-231	IC₅₀	51.1 μM Compound: 47	Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-231	IC₅₀	51.12 μM Compound: 1b	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	6.5 μM Compound: PL ; 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
MDA-MB-453	IC₅₀	34.5 μM Compound: 47	Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-453	IC₅₀	34.56 μM Compound: 1b	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-468	IC₅₀	2.5 μM Compound: 1	Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 22483392]
ME-180	IC₅₀	43.4 μM Compound: 1b	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	43.4 μM Compound: 47	Antitumor activity against human ME-180 cells assessed as cell growth inhibition Antitumor activity against human ME-180 cells assessed as cell growth inhibition	[PMID: 36858050]
MONO-MAC-6	IC₅₀	2.6 μM Compound: 2	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PANC-1	IC₅₀	23.7 μM Compound: 1	Cytotoxicity against human PANC-1 cells in Dulbecco's modified Eagle's medium assessed as reduction in cell viability incubated for 24 hrs by WST-8 cell counting analysis Cytotoxicity against human PANC-1 cells in Dulbecco's modified Eagle's medium assessed as reduction in cell viability incubated for 24 hrs by WST-8 cell counting analysis	[PMID: 37257133]
PBMC	EC₅₀	0.8 μM Compound: 1	Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry	[PMID: 22019229]
PBMC	IC₅₀	2.7 μM Compound: 2	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PC-3	IC₅₀	17.19 μM Compound: 1b	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
PC-3	IC₅₀	17.2 μM Compound: 47	Antitumor activity against human PC-3 cells assessed as cell growth inhibition Antitumor activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 36858050]
SAS	IC₅₀	3 μM Compound: 1a	Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24913712]
Sf21	IC₅₀	2 μM Compound: 99	Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate	10.1039/C1MD00199J
Sf9	IC₅₀	>100 μM Compound: 4, ZINC-58187	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	[PMID: 20580552]
SK-BR-3	IC₅₀	1.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay	[PMID: 22512718]
SK-BR-3	IC₅₀	3.2 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay	[PMID: 22512718]
SK-MEL-28	IC₅₀	5 μM Compound: 2	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
SMMC-7721	IC₅₀	2.43 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 24 hrs Antitumor activity against human SMMC-7721 cells measured after 24 hrs	[PMID: 34669417]
SMMC-7721	IC₅₀	36.05 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 6 hrs Antitumor activity against human SMMC-7721 cells measured after 6 hrs	[PMID: 34669417]
SMMC-7721	IC₅₀	5.41 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 12 hrs Antitumor activity against human SMMC-7721 cells measured after 12 hrs	[PMID: 34669417]
SW480	IC₅₀	12 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
SW480	IC₅₀	7.3 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24828199]
SW-620	IC₅₀	7.4 μM Compound: 1	Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24828199]
SW-620	IC₅₀	7.7 μM Compound: 1	Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
SW982	IC₅₀	3.6 μM Compound: 2	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
THP-1	IC₅₀	1.1 μM Compound: 2	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
U-373MG ATCC	IC₅₀	5 μM Compound: 2	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
U-937	IC₅₀	2.4 μM Compound: 2	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
WI-38	IC₅₀	26.71 μM Compound: Plumbagin	Cytotoxicity against human WI38 cells after 48 hrs by MTT assay Cytotoxicity against human WI38 cells after 48 hrs by MTT assay	[PMID: 30007564]
WRL68	IC₅₀	15.36 μM Compound: PL ; 1	Cytotoxicity against human WRL68 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human WRL68 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]

In Vitro

Plumbagin (0, 5, 10, and 15 μM) induces apoptosis of prostate cancer cell lines, such as DU145, CWR22rv1 and LNCaP, in a dose-dependent manner^[1].
Plumbagin (5, 20 μM) obviously inhibits the invasion of PC3, DU145, and CWR22rv1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

DU145, CWR22rv1, LNCaP and RWPE-1 cells
Concentration:

0, 5, 10, and 15 μM
Incubation Time:

24 hours
Result:

Dose-dependently induced apoptosis of DU145, CWR22rv1 and LNCaP, but showed no effect on RWPE-1 cells at up to 20 μM.

In Vivo

Plumbagin (2 mg/kg, i.p., five days a week for 11 weeks) inhibits the growth of tumor in male athymic nude mice^[1].
Plumbagin (2 mg/kg, i.p., five days a week for 11 weeks) inhibits expression of PKCε, suppresses JAK-2 and Stat3 phosphorylation, and activates Stat3, PCNA, VEGF and MMP-9 in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male athymic nude mice bearing DU145 cells^[1]
Dosage:

2 mg/kg
Administration:

I.P. after 3 days post cell implantation, five days a week.
Result:

Delayed tumor growth by 3 weeks, and reduced tumor weight and volume in mice.

Chemical Information

CAS No. 481-42-5
Appearance Solid
Molecular Weight 188.18
Formula C₁₁H₈O₃
Color Light yellow to orange
SMILES

O=C1C(C)=CC(C2=C1C=CC=C2O)=O
Synonyms

2-Methyljuglone
Structure Classification
- Quinones
- Naphthalene Quinones
- Phenols
- Monophenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All Cell Proliferation/Viability AssayApoptosis AnalysisWBRT-PCRHistological Imaging/Staining

Sort by:

Journal Impact Factor

Int J Biol Macromol

Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. [Abstract]

2021 Jul 31:183:182-192. PMID: 33901557
Int Immunopharmacol

Plumbagin improves myocardial fibrosis after myocardial infarction by inhibiting the AKT/mTOR pathway to upregulate autophagy levels. [Abstract]

2025 Jan 18:148:114086. PMID: 39827666
Crit Rev Eukaryot Gene Expr

Plumbagin Induces Apoptosis in Diffuse Large B-Cell Lymphoma by Modulating the ROS-PI3K-Akt-mTOR Signaling Pathway. [Abstract]

2025;35(2):13-25. PMID: 39957590

Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25. [Abstract]

Effect of indicated Plumbagin (PL) concentration gradients on proliferation of SU-DHL-4 cells in 12, 24, and 36 hours.

Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25. [Abstract]

Flow cytometry analysis of SU-DHL-4 cell apoptosis after stimulation with control: 1.0 and 1.5 μM Plumbagin (PL) for 24 hours.

Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25. [Abstract]

Western blot analysis and quantification of caspase 3, Bcl 2, Bax protein expression in control, and 1.0 and 1.5 μM Plumbagin (PL) treated SU-DHL-4 cells after 24 hours.

Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25. [Abstract]

mRNA expression of catalase, SOD1, and SOD2 as determined by QPCR treated with 1.0 and 1.5 μM Plumbagin (PL).

Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25. [Abstract]

HE staining in tumor tissues of control and Plumbagin (PL) (2 mg/kg, i.p.)-treated DLBCL-xenograft mice.

Solvent & Solubility

In Vitro:

DMSO : ≥ 150 mg/mL (797.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.3141 mL

26.5703 mL

53.1406 mL

5 mM

1.0628 mL

5.3141 mL

10.6281 mL

10 mM

0.5314 mL

2.6570 mL

5.3141 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (11.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (11.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Aziz MH, et al. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008 Nov 1;68(21):9024-32. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.3141 mL	26.5703 mL	53.1406 mL	132.8515 mL
	5 mM	1.0628 mL	5.3141 mL	10.6281 mL	26.5703 mL
	10 mM	0.5314 mL	2.6570 mL	5.3141 mL	13.2852 mL
	15 mM	0.3543 mL	1.7714 mL	3.5427 mL	8.8568 mL
	20 mM	0.2657 mL	1.3285 mL	2.6570 mL	6.6426 mL
	25 mM	0.2126 mL	1.0628 mL	2.1256 mL	5.3141 mL
	30 mM	0.1771 mL	0.8857 mL	1.7714 mL	4.4284 mL
	40 mM	0.1329 mL	0.6643 mL	1.3285 mL	3.3213 mL
	50 mM	0.1063 mL	0.5314 mL	1.0628 mL	2.6570 mL
	60 mM	0.0886 mL	0.4428 mL	0.8857 mL	2.2142 mL
	80 mM	0.0664 mL	0.3321 mL	0.6643 mL	1.6606 mL
	100 mM	0.0531 mL	0.2657 mL	0.5314 mL	1.3285 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Plumbagin

Natural Product Library

Anti-Cancer Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Aging Natural Product Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Quinones Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Plumbagin

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Plumbagin

Natural Product Library

Anti-Cancer Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Aging Natural Product Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Quinones Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Plumbagin

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Plumbagin Related Classifications

Cat. No.: HY-N1497